Stereotactic body radiation therapy (SBRT) for patients with stage I non-small cell lung cancer is applicable to more tumors than sublobar resection by Song, Andrew et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Radiation Oncology Faculty 
Papers Department of Radiation Oncology 
3-1-2021 
Stereotactic body radiation therapy (SBRT) for patients with stage 
I non-small cell lung cancer is applicable to more tumors than 
sublobar resection 
Andrew Song 
Nathaniel R. Evans III 
Scott W. Cowan 
Jenny Guo 
Tingting Zhan 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/radoncfp 
 Part of the Oncology Commons, Radiation Medicine Commons, and the Surgery Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Radiation Oncology Faculty Papers by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Andrew Song, Nathaniel R. Evans III, Scott W. Cowan, Jenny Guo, Tingting Zhan, Bo Lu, and Maria Werner-
Wasik 
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2021;13(3):1576-1583 | http://dx.doi.org/10.21037/jtd-20-2001
Original Article
Stereotactic body radiation therapy (SBRT) for patients with stage 
I non-small cell lung cancer is applicable to more tumors than 
sublobar resection
Andrew J. Song1^, Nathaniel Evans2, Scott Cowan2, Jenny Guo3, Tingting Zhan4, Bo Lu1,  
Maria Werner-Wasik1
1Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; 2Department of 
Surgery, Division of Thoracic Surgery, Thomas Jefferson University, Philadelphia, PA, USA; 3Sidney Kimmel Medical College at Thomas Jefferson 
University, Philadelphia, PA, USA; 4Department of Pharmacology & Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson 
University, Philadelphia, PA, USA
Contributions: (I) Conception and design: M Werner-Wasik, AJ Song, N Evans, S Cowan; (II) Administrative support: AJ Song, J Guo; (III) Provision 
of study materials or patients: M Werner-Wasik, B Lu; (IV) Collection and assembly of data: AJ Song, J Guo; (V) Data analysis and interpretation: M 
Werner-Wasik, AJ Song, T Zhan, N Evans, S Cowan, B Lu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Maria Werner-Wasik, MD. 111 S 11th Street, Suite G-301, Philadelphia, PA 19107, USA. Email: Maria.Werner-Wasik@Jefferson.edu.
Background: Virtually all patients with medically inoperable stage I non-small cell lung cancer (NSCLC) 
can receive stereotactic body radiation therapy. However, the percentage of such patients in whom sublobar 
resection is technically feasible is unknown. This discrepancy can confound clinical trial eligibility and 
designs comparing stereotactic body radiation therapy vs. sublobar resection.
Methods: A total of 137 patients treated with stereotactic body radiation therapy for lung lesions (3/2013–
11/2017) underwent retrospective review. Diagnostic CT chest and PET/CT images, stereotactic body 
radiation therapy dates, and demographic data were collected on 100 of 137 patients. Two experienced board-
certified thoracic surgeons independently reviewed anonymized patients’ pre-stereotactic body radiation 
therapy diagnostic imaging and completed a custom survey about the technical feasibility of sublobar 
resection for each patient. Interrater agreement was measured using Cohen’s kappa coefficient by bootstrap 
methodology. Summary statistics were performed for baseline demographics and tumor characteristics.
Results: Of the 100 patients, 57% were female, with median age of 75 years (range, 52–95 years) and 
Karnofsky Performance Status of 80 (range, 40–100). Most patients (61%) had Stage IA1, T1a tumors. For 
interrater agreement analysis, one patient was removed from each cohort due to inability to locate tumor on 
images, leaving 98 patients analyzed. Comparing Surgeon #1 vs. Surgeon #2, 64 (65.3%) vs. 69 (70.3%) of 
tumors were thought eligible for sublobar resection, respectively (κ=0.414).
Conclusions: Stereotactic body radiation therapy for stage I NSCLC is applicable to more tumors than 
sublobar resection, with ~30–35% of stereotactic body radiation therapy patients unable to undergo sublobar 
resection assessed by pretreatment diagnostic imaging based on technical grounds. This study illustrates 
that clinical trials comparing stereotactic body radiation therapy vs. sublobar resection are limited to only a 
subpopulation of patients with stage I NSCLC.
Keywords: Stereotactic body radiation therapy (SBRT); stereotactic ablative radiotherapy (SAbR); sublobar 
resection; wedge resection; segmentectomy; early stage non-small cell lung cancer (early stage NSCLC)
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Introduction
Stereotactic body radiation therapy (SBRT), also known as 
stereotactic ablative radiotherapy (SAbR), is often offered as 
an alternative to surgery for early stage non-small cell lung 
cancer (NSCLC) patients who are medically inoperable or 
who decline surgery (1). Virtually all of these patients can 
receive SBRT despite their medical shortcomings. SBRT 
has been proven to have a high rate of local control (~90–
95%) with limited toxicity, even with long-term follow-up, 
with the most common recurrences occurring regionally or 
distantly (2). In a pooled analysis of the STARS and ROSEL 
trials, which looked at operable Stage I NSCLC patients, 
SBRT was found to have a higher overall survival of 95% at 
3 years compared to patients who had received lobectomy 
and mediastinal lymph node dissection at 75%, with similar 
recurrence free survival (3). Patients who had received 
surgery had more Grade 3 or higher events than the SBRT 
arms (44% vs. 10%).
An ongoing phase 3 trial, STABLE-MATES, is looking 
to determine if this overall survival difference will be 
observed in a larger patient population, when comparing 
head-to-head sublobar resection vs SBRT with 54 Gy in 
3 fractions for early stage peripheral lesions (4). One of the 
inclusion criteria is whether a patient’s tumor is in a location 
that will allow for a sublobar resection. Sublobar resection, 
performed as a wedge resection or segmentectomy, is more 
akin to SBRT, with recent studies suggesting similar clinical 
outcomes to lobectomy in certain contexts when accounting 
for tumor size and location (5-7). This criterion raises an 
interesting question. What proportion of patients eligible 
for SBRT are not eligible for sublobar resection due to 
technical inability to resect the tumor? To date, there is 
no published literature quantifying this specific parameter 
which could potentially change clinical trial design and 
patient eligibility regarding these modalities in the future, 
as well as specific recommendation for clinical practice 
guidelines.
We report a novel assessment of early stage NSCLC 
patients eligible for and treated with SBRT, but who are not 
amenable to sublobar resection due to technical considerations.
We present the following article in accordance with the 
STROBE reporting checklist (available at http://dx.doi.
org/10.21037/jtd-20-2001).
Methods
The study was conducted in accordance with the Declaration 
of Helsinki (as revised in 2013). The study was approved 
by the Institutional Review Board at Thomas Jefferson 
University (Philadelphia, PA; IRB Control # 17D.549) and 
individual consent for this retrospective analysis was waived.
We identified 137 consecutive patients treated at our 
institution with SBRT for lung lesions from March 2013 
to November 2017. Of these patients, 37 patients were 
removed from analysis for the following reasons: 33 patients 
received SBRT for lung metastases and 4 lacked pre-
SBRT imaging records. For the remaining 100 patients, we 
collected diagnostic CT chest images, PET/CT images, 
SBRT treatment details, and demographic data (Figure 1). 
Staging was reported per AJCC 7th edition.
Two experienced board-certified thoracic surgeons, 
with 7 and 11 years of practice and performing 80 to 100 
surgeries per year for stage I NSCLC at time of study, 
independently reviewed each patient’s anonymized pre-
SBRT diagnostic CT chest scans along with corresponding 
PET/CT images when available. With each patient review, 
the thoracic surgeons filled out a customized survey which 
was created with input from radiation oncologists and 
thoracic surgeons to evaluate technical feasibility of a 
sublobar resection of primary lung lesions (Figure 2). This 
survey asked questions on the following:
(I) Ability to identify the lung tumor in question (yes/no);
(II) Technical feasibility of any sublobar resection (yes/no); 
(III) Technical feasibility of wedge resection (yes/no);
(IV) Technical feasibility of segmentectomy (yes/no).
Surgeons were asked to provide the best answer to each 
of the questions. If the surgeons answered “no” to question 
#III, they were further prompted to provide reasons for not 
being able to perform wedge resection including:
i. The tumor is too deep within the lung;
ii. Inadequate margin due to tumor size;
iii. Inadequate margin due to tumor location;
iv. The tumor is too small to be palpable;
v. Other (free-form response).
Similarly, if the surgeons answered “no” to question #IV, 
then reasons against segmentectomy included:
i. The tumor is not clearly confined to one segment;
ii. Inadequate margin due to tumor size;
iii. Inadequate margin due to tumor location;
iv. Segmental anatomy is not clear on imaging;
v. Other (free-form response).
Statistical analysis 
Interrater agreement between the surgeons was measured 
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Assessed for eligility (n=137)
Thoracic surgeon #1










Pre-SBRT imaging reviewed for sublobar 
resection feasibility via survey (n=100)
Excluded
- Non-lung primary, metastatic lung lesions (n=33)
- Lack of pre-SBRT imaging for review (n=4)
Figure 1 CONSORT diagram. *, each surgeon was unable to identify one lesion of interest on pre-SBRT imaging for one patient. These 
were different patients, so for interrater analysis, both of these patients were excluded.
using Cohen’s kappa coefficient by bootstrap methodology (8). 
Kappa coefficient (κ) ranges were determined as follows (9):
i. κ ≤0 as indicating no agreement;
ii. 0.01≥ κ ≤0.20 as none to slight;
iii. 0.21≥ κ ≤0.40 as fair;
iv. 0.41≥ κ ≤0.60 as moderate;
v. 0.61≥ κ ≤0.80 as substantial and;
vi. 0.81≥ κ ≤1.00 as almost perfect agreement.
For reasons against technical feasibility of wedge 
resection (question #IV) or segmentectomy (question #VI), 
we examined interrater agreement analysis for patients 
where both Surgeon #1 and Surgeon #2 were in consensus 
that the lesion was not amenable to wedge resection or 
segmentectomy. In the event that a surgeon provided 
multiple responses for a lesion, interrater analysis was 
determined through partial agreement. For example, if 
Surgeon #1 responds ‘i’ and Surgeon #2 responds ‘i/ii’, we 
consider the second response to be ‘i’ and thus qualify as a 
match to the first response. On the other hand, If Surgeon 
#1 responds ‘i’ and Surgeon #2 responds ‘ii/iii’, then we 
would consider the second response to be ‘ii’ (or ‘iii’) and 
not qualify as a match to the first answer.
Summary statistics were performed for baseline 
demographics, tumor characteristics, and surgeon-provided 
reasons against sublobar resection techniques. Statistics 
were analyzed with R (version 3.5.1).
Results
Patient demographics
Of the 100 patients, 57% were female and 43% were male. 
Median age at SBRT was 75 years (range, 52–95 years) 
and median KPS was 80 (range, 40–100). The majority 
of patients (61%) had stage IA1, T1a tumors, followed by 
stage IA2, T1b (22%), and stage IB, T2a (17%).
Individual surgeon responses
Surgeon #1 identified lesions from 99 patients for the 
available pre-SBRT imaging. Surgeon #2 also identified 
99 lesions from the pre-SBRT imaging. However, these 
lesions were in separate patients, so after these two patients 
were removed, 98 patients underwent further analysis.
According to Surgeon #1, of these 98 patients, 64 (65.3%) 
were amenable to sublobar resection. Of these, 64 (100%) 
had the option of wedge resection as feasible while 42 
(65.6%) were considered feasible for segmentectomy. The 
most common reason against wedge resection was “depth of 
tumor in lung” for 22 patients (64.7%). The most common 
reason against segmentectomy was “inadequate margin due 
to tumor location” and “segmental anatomy not clear on 
imaging”, both with 23 responses (41.1%).
For Surgeon #2, 69 (70.4%) of tumors were amenable 
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to sublobar resection. Of these, 58 (84%) had the option 
of wedge resection as feasible while 42 (62.3%) were 
considered feasible for segmentectomy. When prompted 
for reasons against a sublobar resection, at times Surgeon 
#2 provided multiple responses (e.g., ‘A’ and ‘B’), with 
10 patients (24 responses) for wedge resection and 
14 patients (29 responses) for segmentectomy, so all of these 
were reported. The most common reason against wedge 
resection for Surgeon #2 was also “depth of tumor in lung” 
for 32 patients (80%). The most common reason against 
segmentectomy was different, with “tumor not clearly 
confined to one segment” in 44 patients (80%). Please see 
Figure 3 for detailed response breakdown.
Interrater agreement analysis
For interrater agreement analysis, one patient each was 
removed from each set of surgeon responses due to a 
response of “inability to identify the tumor” on images. 
These patients were different, thus leaving 98 unique 
patients for analysis comparing responses between Surgeon 
#1 and Surgeon #2.
When comparing technical feasibility for sublobar 
resection, there was moderate interrater agreement (κ=0.414). 
For wedge resection feasibility, interrater agreement was 
slightly higher (κ=0.473). For segmentectomy, the interrater 
agreement was fair (κ=0.225).
When examining reported reasons against wedge 
resection, there was moderate interrater agreement (κ=0.431). 
However, for reasons against segmentectomy, there was only 
slight agreement (κ=0.052). See Table 1.
Discussion
Our results suggest that approximately 30–35% of patients 
who are able to receive SBRT are not able to undergo 
sublobar resection, based on technical considerations 
from pretreatment diagnostic imaging. This represents 
a subpopulation of early stage NSCLC patients that is 
often overlooked in the current treatment paradigm. The 
proportion of patients deemed eligible for wedge resection 
(~60%) was higher than segmentectomy (~40%), with 
moderate to fair interrater agreement. Agreement on 
reasons against segmentectomy was also relatively lower 
than that on wedge resection.
Although lobectomy is the standard of care for medically 
operable patients (10), there exists a subset of patients in 
whom sublobar resection may be considered. The NCCN 
guidelines define this as patients with poor pulmonary 
reserve, major comorbidities, and/or peripheral nodule 
≤2 cm in size with ≥50% ground-glass appearance or long 
doubling time (1). These same patients are oftentimes also 
eligible for SBRT as it is felt that SBRT has minimal risks 
associated with treatment of such patients with resulting 
stable pulmonary function post-treatment. Additionally, 
more recent studies have shown that sublobar resection 
can be comparable to lobectomy for clinical outcomes 
after adjusting for confounders and also factoring in 
1. Are you able to identify the lung tumor in question? 
a. Yes
b. No
2. Is this tumor amenable to a sublobar resection ?
a. Yes
b. No
3. If yes, can wedge resection be performed? 
a. Yes
b. No
4. If not wedge, why?
a. The tumor is too deep within the lung
b. Inadequate margin due to tumor size
c. inadequate margin due to tumor location
d. The tumor is too small to be palpable
e. Other: ___fill in the blank_______
5. If yes, can segmentectomy be performed? 
a. Yes
b. No
6. If not segmentectomy, why?
a. The tumor is not clearly confined to one segment
b. Inadequate margin due to tumor size
c. inadequate margin due to tumor location
d. segmental anatomy is not clear on imaging
e. Other: ___fill in the blank_______
Figure 2 Thoracic surgeon survey with sample image.
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size and location of lesions while preserving pulmonary 
function (7,11-15). An earlier meta-analysis of stage I 
NSCLC patients showed no overall survival differences 
between these surgical techniques at 1, 3, and 5 years 
with a subsequent, separate meta-analysis also showing no 
differences in disease-free and overall survival for patients 
intentionally selected for sublobar resection when compared 
to their lobectomy counterparts with small, peripheral 
lesions (6,12). SBRT has also been evaluated for early stage 
peripheral lesions in medically operable patients in the 
setting of a single-arm phase II clinical trial, RTOG 0618, 
with 26 patients evaluated and achieving relatively high local 
control (96%) and low rates of surgical salvage and adverse 
events while preserving pulmonary function (16). SBRT 
is also more cost-effective for marginally operable stage I 
NSCLC patients when compared to either wedge resection 
or lobectomy (17). Markov modeling of medically operable 
patients stratified by smoking history suggested SBRT was 
also similar to surgery when comparing quality-adjusted 
life years (QALY) (18). Through a propensity score-
matched analysis of National Cancer Database, an increased 
mortality risk associated with more extensive surgery and 
older age were found when compared to SBRT. Although 
SBRT has been traditionally associated with treatment of 
Figure 3 Individual surgeon survey responses. (A) A, the tumor is not clearly confined to one segment; B, inadequate margin due to tumor 
size; C, inadequate margin due to tumor location; D, segmental anatomy is not clear on imaging; E, other (free-form response). Surgeon 
#2 provided multiple responses for some patients, thus these have all been compiled leading to more than 55 responses (total 70). (B) A, the 
tumor is too deep within the lung; B, inadequate margin due to tumor size; C, inadequate margin due to tumor location; D, the tumor is 
too small to be palpable; E, other (free-form response). Surgeon #2 provided multiple responses for some patients, thus these have all been 
compiled leading to more than 40 responses (total 54).
Table 1 Interrater agreement analysis
Technical feasibility Kappa coefficient (κ) Magnitude P value
Sublobar resection 0.414 Moderate <0.001
Wedge resection 0.473 Moderate <0.001
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peripheral lung lesions due to early experiences with excess 
toxicity for centrally located tumors (19), our improved 
understanding for dosing and constraints for organs at risk 
has led to more patients with centrally located tumors to 
now be eligible for SBRT. A recent phase I/II study, RTOG 
0813, determined that central tumors could be treated 
comparably to peripheral tumors with a MTD of 12 Gy per 
fraction (20). In recent years, the national trend away from 
lobectomy and towards sublobar resection and SBRT makes 
these findings more pertinent (21). Therefore, we believe 
that our comparison of these two treatment modalities is 
important for being taken into consideration for managing 
a subpopulation of early stage NSLC patients. 
Our study is limited to two board certified thoracic 
surgeons and could be further improved with additional 
participation. In addition, while our study does analyze 
strengths of interrater agreement, we lack intrarater 
reliability. The latter could provide additional insights 
on the consistency of assessment for which lesions are 
deemed resectable by an individual. External validation of 
the customized survey will introduce additional data for 
interrater agreement analysis.
Although our surgeons had moderate interrater 
agreement regarding ineligibility for wedge resection 
and corresponding reasons against wedge resection, the 
interrater agreement for segmentectomy was relatively 
lower with fair interrater agreement for ineligibility and 
even lower for the reasons against segmentectomy. This 
is an interesting finding, as segmentectomy is a more 
complex procedure than wedge resection, with the latter 
a nonanatomic resection. This disparity is likely multi-
factorial, including surgeon-specific training, experience 
and preferential practice as well as patient anatomies and 
tumor location, size, and appearance.
Current practice guidelines for early stage NSCLC 
are available from several organizations, including the 
American Society for Radiation Oncology, European Society 
for Medical Oncology, National Comprehensive Cancer 
Network, and Spanish Society of Medical Oncology. These 
guidelines tend to favor lobectomy, followed by sublobar 
resection, and lastly by SBRT (1,22-24). For medically 
operable patients, SBRT is recommended against unless 
in the setting of a clinical trial. Part of this rationale is that 
surgery can provide additional nodal pathology for staging 
purposes so that there remains the risk of under-staging due 
to occult disease, with PET/CT scans having a false-negative 
rate approximately 10–15% for clinical stage I disease 
(25-27). However, a meta-analysis of over 1,000 patients 
from 10 studies, examined the negative predictive value of 
PET/CT and found NPV as high as 94% for mediastinal 
metastases for T1 disease (28). Therefore, we believe 
that for some early stage NSCLC patients who are not 
resectable candidates or who will elect to decline surgery, 
the benefits from invasive nodal staging should be balanced 
by the risks and costs associated with such a strategy. There 
are several options for mediastinal staging, including no 
invasive mediastinal staging, endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA), and 
mediastinoscopy. When comparing these options for QALY 
in a single payer system, there were relatively small real-
world disparities between these modalities (5.80 vs. 5.87 vs. 
5.86 QALYs, respectively), resulting in approximately 3–3.5 
weeks’ difference of optimal health (29). When comparing 
the incremental cost-effectiveness ratios (ICER) for these 
mediastinal staging options, for cN0 patients with low risk 
(<2.5%) of pN2 involvement, invasive mediastinal staging 
is not cost-effective with a ICER of ~$20,016.68/QALY for 
EBUS-TBNA alone and ~$1,076,163.63/QALY for EBUS-
TBNA with mediastinoscopy. In addition, we should also 
consider the operative mortality associated with surgical 
resection, ranging from 1.1% for wedge resection, 1.8% 
for segmentectomy, and 2.0% for lobectomy patients (30). 
These elements should be factored in the decision-making 
process when managing early stage NSCLC patients, 
especially for those who may be borderline medically 
operable or are not optimal candidates for resectability.
Clinical trials attempting to compare surgery and SBRT 
have faced barriers with accrual and questions of equipoise 
(3,31). Ongoing phase III trials, such as the VALOR trial (32) 
comparing lobectomy or segmentectomy with mediastinal 
lymph node sampling (adjuvant chemotherapy for positive 
lymph nodes) vs SBRT and the SABRTOOTHv1 trial (33) in 
the UK which compares sublobar resection +/− intraoperative 
brachytherapy vs. SBRT, will help elucidate the value of SBRT 
in medically operable patients in the setting of anatomic and 
nonanatomic resections as well as utility of brachytherapy with 
sublobar resection. Future clinical trials hoping to compare 
these treatment modalities may take into consideration that a 
subpopulation of patients will be considered medically operable 
but are ineligible for sublobar resection due to technical 
reasons, which will affect screening and potential enrollment 
success. In addition, we believe that prior clinical trials would 
have excluded such patients from enrollment and analysis, 
which could lead to a bias in patient selection and ultimately 
affecting the outcomes of comparing these modalities.
Our study is the first of its kind to report a quantifiable 
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estimate on the proportion of early stage NSCLC patients 
who are treatable with SBRT, but are not appropriate for 
sublobar resection based on technical criteria. Results from 
prior clinical trials may need to be qualified by extrapolating 
outcomes only to patients who are both medically and 
technically operable. This specific subpopulation of patients 
should be considered when developing practice guidelines 
for care in early stage NSCLC patients as well as for 
designing eligibility criteria and screening for clinical trials 
comparing sublobar resection with SBRT.
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